Prot# EZN-2208-01: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks in Patients with Advanced Solid Tumors or Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date8/22/07 → 8/22/10

Funding

  • Enzon, Inc. (EZN-2208-01)